Obermatt
See Similar Stocks →

Flags

Financial distress

Valneva

PAR:VLA · FR0004056851
BiotechnologySmall

360

21
Profit price34
Owner Earnings Yield1
Dividend Yield1
Price/Sales83
Price/Book13
Return on Capital68
Cash Return on Capital40
Return on Equity19
EBIT Margin46
Gross Profitability29
Accruals80
Owner Earnings Margin61
Sales growth26
Profit growth32
Reinvestment54
Price momentum35
Debt load26
Refinancing86
Debt Payback1
Liquidity60
Analyst ratings24
Opinion Changes50
Price Target Upside59
Market mood13
Value Creation0/20not creating value
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

Valneva doesn't consistently earn more than its cost of capital, so it isn't yet creating shareholder value.

Profile

CountryFrance
IndustryBiotechnology
SizeSmall
TypePublic Company
ExchangeENXTPA
Founded1999
Employees544
Websitevalneva.com
ISINFR0004056851
Last UpdateApr 2, 2026
Indices
CAC All (France)NASDAQ (USA)SBF 120 (France)
Themes
ImmunologyInfectious DiseasesVaccinesBiotechnologyHealth CareMedical

Description

Valneva SE operates as a specialty vaccine company. The company develops, manufactures, and commercializes prophylactic vaccines for infectious diseases addressing unmet medical needs. The company takes a highly specialized and targeted approach, ap…

Analysis

Middle-of-the-road

Valneva SE is a middle-of-the-road business: neither the economics nor the price stand out from the peer group.

Valuation data is not available for this company.

The trajectory is moderate and the balance sheet is stretched. The company scores 0/20 on our value-creation score: not creating value.

Nothing is flagged here: no red or amber gates, no divergence between profits and cash. That is itself information: the numbers are straightforward. As always: this describes the company's numbers; it is not a recommendation.

360° rank · history

1007550250
26
2026

All-time high

78

Mar 2026

All-time low

26

Jun 2026

Average rank

52

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
83
—
—
—
Price/Earnings
71
—
—
—
Price/Book
13
—
—
—
Dividend Yield
1
—
—
—
Value (overall)
65
—
—
—

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Valneva with its peers
ABIVAX
PAR:ABVX
26
CountryFrance
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
BioNTech
NSQ:BNTX
11
CountryGermany
IndustryBiotechnology
SizeLarge
Full Stock Analysis →
AC Immune
NMQ:ACIU
68
CountrySwitzerland
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Transgene
PAR:TNG
15
CountryFrance
IndustryBiotechnology
SizeX-Small
Full Stock Analysis →
Innate Pharma
PAR:IPH
54
CountryFrance
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Immunocore
NSQ:IMCR
40
CountryUK
IndustryBiotechnology
SizeSmall
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →